Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.16

0.01 (0.03%)

, BP

BP

$35.14

-0.02 (-0.06%)

20:25
07/31/17
07/31
20:25
07/31/17
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Pfizer (PFE), consensus 66c... BP (BP), consensus 18c... Emerson Electric (EMR), consensus 69c... Ecolab (ECL), consensus $1.12... Sprint (S), consensus (1c)... Cummins (CMI), consensus $2.57... Incyte (INCY), consensus (3c)... Royal Caribbean Cruises (RCL), consensus $1.67... Archer-Daniels-Midland (ADM), consensus 52c... Under Armour (UAA), consensus (6c)... Xerox (XRX), consensus 80c... Lumber Liquidators (LL), consensus (7c).

PFE

Pfizer

$33.16

0.01 (0.03%)

BP

BP

$35.14

-0.02 (-0.06%)

EMR

Emerson

$59.61

0.08 (0.13%)

ECL

Ecolab

$131.67

-0.25 (-0.19%)

S

Sprint

$7.98

-0.24 (-2.92%)

CMI

Cummins

$167.90

0.68 (0.41%)

INCY

Incyte

$133.29

-2.45 (-1.80%)

RCL

Royal Caribbean

$113.07

-0.32 (-0.28%)

ADM

Archer Daniels

$42.18

0.4 (0.96%)

UAA

Under Armour

$20.02

0.58 (2.98%)

UA

Under Armour

$18.11

0.75 (4.32%)

XRX

Xerox

$30.67

0.24 (0.79%)

LL

Lumber Liquidators

$24.71

-0.87 (-3.40%)

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 27

    Aug

  • 28

    Aug

PFE Pfizer
$33.16

0.01 (0.03%)

07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/20/17
FBCO
07/20/17
DOWNGRADE
Target $36
FBCO
Neutral
Pfizer downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38. The shares closed yesterday up 26c to $33.62. The analyst, who notes he's long been a supporter of Pfizer and continues to see opportunities for upside over the long-term, believes the stock's upside drivers are more limited over the next year. Divan prefers other names in the Major Pharmaceuticals space, such as Johnson & Johnson (JNJ) and Merck (MRK). Growth of Pfizer's Ibrance is slowing while global Prevnar sales are flat to declining, Divan tells investors in a research note. He adds that the company is facing two meaningful patent expirations over the next 18 months with Viagra, Lyrica.
BP BP
$35.14

-0.02 (-0.06%)

06/21/17
MACQ
06/21/17
DOWNGRADE
MACQ
Underperform
BP downgraded to Underperform from Neutral at Macquarie
Macquarie analyst Iain Reid downgraded BP to Underperform following a reduction in the firm's oil price estimates saying the majors will slip back into deficits and have further, painful cost reductions. The firm lowered its its second half 2017 Brent forecast to $54.15 from $58.76 and WTI forecast to $52.15 from $56.75, 2018 Brent forecast to $49.33 from $55.75 and WTI forecast to $46.08 from $52.50, and 2019 Brent forecast to $65 from $70 and WTI forecast to $60 from $65.
07/26/17
SOCG
07/26/17
DOWNGRADE
SOCG
Hold
BP downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Irene Himona downgraded BP to Hold due to higher relative valuation, lower ROACE, and lower organic free cash flow yield versus the sector.
07/11/17
BERN
07/11/17
NO CHANGE
BERN
Oil price forecast cut at Bernstein
Bernstein analysts lowered their 2017 and 2018 oil price forecasts to $50 per barrel for both years. As reasons for the drop, the firm cited higher U.s. shale efficiency, their belief that elevated production levels will last longer than previously expected, and their belief that OPEC cuts will be insufficient to counter increased production by Libya, Iran and Nigeria. Publicly traded companies in the oil space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT).
05/02/17
BERN
05/02/17
NO CHANGE
BERN
BP shares should be bought ahead of 2H17, says Bernstein
Bernstein analyst Oswald Clint says that BP's Q1 results indicate that the company's upstream and downstream businesses are "beginning to rev." The analyst expects the company's volume, margin and cash flow to all reach positive turning points in 2H17, and he recommends that investors buy the stock.
EMR Emerson
$59.61

0.08 (0.13%)

06/19/17
JMPS
06/19/17
INITIATION
JMPS
Outperform
Emerson initiated with an Outperform at JMP Securities
JMP Securities analyst Joseph Osha started coverage of Emerson with a $70 price target and an Outperform rating. The analyst says that the company is well-managed , "has higher margins than most of its competitors," and "has a solid dividend yield."
05/15/17
STFL
05/15/17
NO CHANGE
STFL
Emerson shares poised to rebound, says Stifel
After meeting with Emerson's CEO, Stifel analyst Robert McCarthy is more upbeat about the company's Automation Solutions and Commercial & Residential Solutions units. The analyst says that the CEO is confident that the company's margins can rise. McCarthy raised his price target on the name to $67 from $65 and keeps a Buy rating.
03/03/17
HSBC
03/03/17
UPGRADE
HSBC
Hold
Emerson upgraded to Hold from Reduce at HSBC
HSBC analyst Michael Hagmann upgraded Emerson to Hold and raised its price target to $55 from $44 saying risk/reward is more balanced. The analyst believes management has a better handle on execution combined with more achievable FY21 guidance of $3.85 given on investor day.
04/04/17
WELS
04/04/17
NO CHANGE
WELS
ABB acquisition should provide support for Rockwell Automation, says Wells Fargo
Following the announcement that ABB (ABB) plans to acquire Bernecker & Rainer Industrie- Elektronik, Wells Fargo analyst Richard Kwas says the deal should provide support for Rockwell Automation's (ROK) shares, and should be a positive read through for the latter. The acquisition fills gaps for ABB in discrete automation, the analyst notes, adding that ABB could become a "more formidable competitor" in discrete. Separately, Kwas acknowledges that he had thought that Bernecker & Rainer Industrie- Elektronik may have been a "good fit" for Emerson (EMR), which he expects to execute additional M&A later in the year.
ECL Ecolab
$131.67

-0.25 (-0.19%)

05/26/17
JPMS
05/26/17
UPGRADE
Target $138
JPMS
Overweight
Ecolab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Ecolab to Overweight and raised his price target for the shares to $138 from $120. The company's volume prospects are improving due to higher rig counts, Zekauskas tells investors in a research note.
06/01/17
OPCO
06/01/17
NO CHANGE
Target $141
OPCO
Outperform
Ecolab price target raised to $141 from $133 at Oppenheimer
Oppenheimer analyst Scott Schneeberger raised his price target for Ecolab to $141 saying he's "incrementally constructive" on the shares following recent investor meetings with management. Ecolab is the early stages of its $125B global market opportunity with just 11% share, Schneeberger tells investors in a research note. He sees an"accelerating growth inflection point" for the company and keeps an Outperform rating on the name.
04/03/17
04/03/17
UPGRADE
Target $118

Neutral
Ecolab upgraded to Neutral on achievable 2017 guidance at Nomura
As previously reported, Nomura upgraded Ecolab to Neutral from Reduce and raised its price target to $118 from $99. Analyst Dan Dolv believes 2017 earnings guidance is achievable saying the energy model points to modest growth and a pricing recovery can offset some commodity headwinds.
04/03/17
NOMU
04/03/17
UPGRADE
NOMU
Neutral
Ecolab upgraded to Neutral from Reduce at Nomura
S Sprint
$7.98

-0.24 (-2.92%)

07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
05/30/17
MOFT
05/30/17
NO CHANGE
MOFT
U.S. telecom sector upgraded to Neutral from Sell at MoffettNathanson
MoffettNathanson analyst Craig Moffett upgraded the U.S. telecom sector to Neutral from Sell. As reasons for the upgrade, the analyst cited valuation, lack of near-term negative catalysts, interest rate easing, and a potential merger between Sprint (S) and T-Mobile (TMUS). Other stocks in the sector include Verizon (VZ) and AT&T (T). The firm today upgraded AT&T to Neutral from Sell.
06/27/17
JEFF
06/27/17
NO CHANGE
JEFF
Jefferies sees Sprint takeover by Comcast, Charter as less likely
Jefferies analyst Mike McCormack says this morning's Wall Street Journal report exclusive talks between Sprint (S) and Comcast (CMCSA)/Charter (CHTR) is not surprising. He believes the cable operators are looking for better MVNO terms and that an outright acquisition or equity stake is less likely. The report provides an indication of just how far apart Sprint and T-Mobile (TMUS) may be in any discussions, McCormack tells investors in a research note. The exclusive talks may also push T-Mobile closer to DISH (DISH), the analyst adds.
05/30/17
BTIG
05/30/17
NO CHANGE
BTIG
Verizon shares could rise to $51 but outlook still mixed, says BTIG
BTIg analyst Walter Piecyk believes that Verizon's (VZ) stock can rise to $51. He notes that the company's wireless "margins and churn are still near record levels," while Sprint's (S) CEO expects prices for unlimited data plans to rise. Additionally, the analyst believes that the chances of Verizon making "a large dilutive acquisition" have decreased, while Verizon would benefit from a merger of Sprint and T-Mobile (TMUS). However, the analyst lowered his estimates for Verizon ,and he thinks that the company's dividend could be at risk over the longer term. Moreover, he warns that the stock could come under pressure if the T-Mobile/Sprint merger falls through, while a new , "well-funded" competitor could enter the wireless space. He keeps a Neutral rating on Verizon.
CMI Cummins
$167.90

0.68 (0.41%)

05/02/17
05/02/17
NO CHANGE
Target $368

Overweight
Piper analysis suggests Tesla can succeed in electric trucks
Piper Jaffray analyst Alexander Potter's analysis suggests Tesla's (TSLA) electric trucks could generate payback times of less than two years, based primarily on fuel and maintenance cost savings relative to diesel trucks. While unanswered questions remain, Tesla is likely to succeed in electric semi trucks given its battery cost advantage, Potter tells investors in a research note. He admits that it's easy to see why many investors met Tesla's truck announcement with skepticism. Relative to consumers, fleets constitute a "less forgiving market segment" given the strict return-on-investment adherence, Potter writes. The analyst has an Overweight rating on Tesla with a $368 price target. He believes that outside of Wabco (WBC), most truck stocks "seem ripe for disruption." The analyst has Underweight ratings on Allison Transmission (ALSN) and Meritor (MTOR) and Neutral ratings on Cummins (CMI), Paccar (PCAR) and Navistar (NAV).
06/05/17
WELS
06/05/17
NO CHANGE
WELS
May truck orders declined more than expected, says Wells Fargo
Wells Fargo analyst Andrew Casey notes May Class 5-8 truck orders increased 20% year-over-year but declined 11% from April. The month-over-month decline was driven by a 30% Class 8 order decline, partially offset by a 13% Class 5-7 order increase, Casey tells investors in a research note. He notes that May's 16,800 Class 8 order intake was well beneath his channel check-based 21,000-24,000 net order expectation. The analyst views ACT Research's truck data for May as a short-term negative for Cummins (CMI), Eaton (ETN), Paccar (PCAR) and Navistar (NAV).
06/22/17
WELS
06/22/17
NO CHANGE
WELS
Earthmoving market trends positive, says Wells Fargo
After speaking with 20 "U.S. earthmoving market participants," including Caterpillar (CAT) and Deere (DE), Wells Fargo says that the market appears to be "tightening." Wells says that activity in "most regions" showed "broad-based improvement" through Q2. Wells adds that manufacturers seem to have trouble keeping up with demand. Wells says its checks bode well for Caterpillar, Deere, Cummins (CMI), Eaton (ETN) and Parker-Hannifin (PH). It keeps Outperform rating on Caterpillar and Cummins.
05/03/17
FBCO
05/03/17
NO CHANGE
Target $196
FBCO
Outperform
Cummins price target raised to $196 from $173 at Credit Suisse
Credit Suisse analyst Jamie Cook raised his price target for Cummins to $196 from $173 after it beat and raised 2017 estimates materially. The analyst reiterates an Outperform rating on the shares.
INCY Incyte
$133.29

-2.45 (-1.80%)

07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Incyte, NewLink have positive read through from trial failure, says SunTrust
SunTrust analyst PEter Lawson says that the failure of AstraZeneca's (AZN) PD-L1/CTLA4 combo to hit its progression free survival primary endpoint is positive for Incyte (INCY) and NewLink (NLNK0. The analyst says that the failure "relives a competitive concern" for the companies. He keeps a $145 price target and a Buy rating on Incyte.
07/14/17
LEER
07/14/17
NO CHANGE
LEER
Acquisition of Incyte would make sense for Gilead, says Leerink
Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Incyte could see a 9% increment in value, says Oppenheimer
Oppenheimer analyst Jay Olson says Incyte's shares could see a 9% increment in value if the July 25 pipeline update on Olumiant is favorable pointing to a resubmission post-CRL without any new clinical trials required. Separately, Incyte's valuation could reduce by around 11% in the analyst's worst case scenario if read across from MYSTIC is negative based on a positive result for the PD-L1 plus CTLA-4 combo versus chemo in 1L NSCLC all comers.
06/12/17
LEER
06/12/17
NO CHANGE
Target $90
LEER
Outperform
Eli Lilly price target lowered to $90 from $93 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.
RCL Royal Caribbean
$113.07

-0.32 (-0.28%)

07/24/17
GSCO
07/24/17
INITIATION
Target $123
GSCO
Neutral
Royal Caribbean initiated with a Neutral at Goldman Sachs
BofA/Merrill analyst Andrew Didora initiated Royal Caribbean with a Neutral and a $123 price target saying multiple expansion will be difficult given accelerating industry capacity growth.
07/20/17
JPMS
07/20/17
UPGRADE
Target $130
JPMS
Overweight
Royal Caribbean upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Joseph Greff upgraded Royal Caribbean to Overweight and raised his price target for the shares to $130 from $111. The analyst views the current valuation as "undemanding" and notes his recent channel checks suggest continued good operating momentum. He sees 2018 as another year of mid-to high teens earnings growth for Royal Caribbean.
07/20/17
07/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying the window to buy Nike is closing as earnings and North America sales growth rates are likely troughing. 2. B&G Foods (BGS) upgraded to Buy from Neutral at Citi with analyst Cornell Burnett saying the second quarter should mark a positive inflection in organic sales after five consecutive quarters of declines. 3. HP Inc. (HPQ) upgraded to Outperform from Sector Perform at RBC Capital with analyst Amit Daryanani saying he sees a "string of beats/raises" ahead amid stabilizing PC fundamentals and market share gains as Lenovo struggles. 4. Royal Caribbean (RCL) upgraded to Overweight from Neutral at JPMorgan with analyst Joseph Greff saying he views the current valuation as "undemanding" and notes his recent channel checks suggest continued good operating momentum. 5. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Wedbush with analyst Nick Setyan saying investors understand that the company could report weaker than expected results and his other concerns about the company "are well understood." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/17
STFL
07/25/17
NO CHANGE
STFL
Royal Caribbean should be bought on any 'irrational' weakness, says Stifel
Stifel analyst Steven M. Wieczynski does not expect Royal Caribbean's Q2 results to significantly beat expectations, and he thinks investors' expectations for the results may be "unrealistic," particularly regarding the anticipation of increases in the company's 2017 guidance. However, he recommends buying the stock on any "irrational" weakness following the results, as he thinks that the company's 2018 results could beat his expectations and expects the company's multiple and capital returns to increase. He keeps a $125 price target and a Buy rating on the stock.
ADM Archer Daniels
$42.18

0.4 (0.96%)

03/01/17
FBCO
03/01/17
NO CHANGE
Target $46
FBCO
Neutral
New ethanol proposal may not be catalyst for Archer Daniels, says Credit Suisse
Credit Suisse analyst Robert Moskow notes that a group of refiners have provided a proposal to the new U.S. administration that would give some sought after changes to regulations in the ethanol industry. If the proposal gains traction, it may pave the way for higher consumption of ethanol by reducing regulations on the use of E15, the analyst points out. However, he cautions investors about viewing it as a catalyst for positive earnings revisions for Archer Daniels as the White House claims it has no immediate plans to change the compliance structure for ethanol, according to Bloomberg. Moskow reiterates a Neutral rating and $46 price target on the shares.
06/01/17
06/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Archer Daniels (ADM) downgraded to Hold from Buy at Argus with analyst David Coleman saying he expects the company's profits to be lowered by grain oversupplies for the rest of this year. He thinks that the company's dividend increases may be "limited" going forward. 2. CAE (CAE) downgraded to Hold from Buy at TD Securities with analyst Tim James citing valuation. 3. Sinopec Shanghai (SHI) downgraded to Sell from Neutral at Citi. 4. Rayonier Advanced Materials (RYAM) downgraded to Hold from Buy at Vertical Research with analyst Chip Dillon citing valuation. 5. Fox Factory (FOXF) downgraded to Neutral from Buy at CL King with analyst Scott Stember citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/17
ARGS
06/01/17
DOWNGRADE
ARGS
Hold
Archer Daniels downgraded to Hold from Buy at Argus
Argus analyst David Coleman downgraded Archer Daniels as he expects the company's profits to be lowered by grain oversupplies for the rest of this year. He thinks that the company's dividend increases may be "limited" going forward.
01/06/17
01/06/17
DOWNGRADE
Target $48

Market Perform
Archer Daniels downgraded to Market Perform at BMO Capital
As previously reported, BMO Capital analyst KennethZaslow downgraded Archer Daniels Midland to Market Perform from Outperform and lowered his price target on the stock to $48 from $51, citing his more cautious stance on ethanol, U.S. crush margins, and the outlook beyond the winter in light of the abundant crop in South America and limited farmer selling of corn.
UAA Under Armour
$20.02

0.58 (2.98%)

07/25/17
DBAB
07/25/17
DOWNGRADE
Target $17
DBAB
Sell
Under Armour downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Paul Trussell downgraded Under Armour (UAA) to Sell with an unchanged price target of $17. The performance apparel maker closed yesterday down 37c to $20.27. The analyst says a "difficult and promotional selling environment along with segmentation challenges" weaken his confidence in the company's near-term results. Even amid weak investor sentiment, Under Armour won't get a pass on potentially weak Q2 results, Trussell tells investors in a research note. He views the company's growth story as "challenged" and questions the "expensive" valuation. The analyst this morning also upgraded DSW (DSW) and Big Lots (BIG) to Buy.
07/31/17
JEFF
07/31/17
NO CHANGE
Target $28
JEFF
Buy
Jefferies a buyer of Under Armour into Q2 results
In a research note previewing the quarter, Jefferies analyst Randal Konik says Under Armour (UAA) shorts are "too aggressive" while sell-side analysts are "not studying" the stock's risk/reward. He believes "too much fear/hate" has created a "dislocation" in Under Armour shares. The analyst highlights the company's leaner inventories, the upcoming launch of Curry 4, easier compares ahead and strong athletic trends. Konik is a buyer of Under Armour into the Q2 results, but admits the numbers "shouldn't be great." He keeps a Buy rating on the shares with a $28 price target.
07/25/17
07/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Sell from Hold at Deutsche Bank with analyst Paul Trussell saying a "difficult and promotional selling environment along with segmentation challenges" weaken his confidence in the company's near-term results. 2. Snap (SNAP) downgraded to Neutral from Buy with analyst Kevin Rottinghaus citing monetization concerns and increasing pressure from Facebook (FB) competition. 3. Cytori Therapeutics (CYTX) downgraded to Neutral from Buy at B. Riley with analyst Andrew D'Silva citing the STAR trial results, which missed both primary and secondary endpoints. The analyst cut his price target for the shares to 50c from $2.30. 4. lululemon (LULU) downgraded to Hold from Buy at Stifel with analyst Jim Duffy citing valuation. 5. Power Integrations (POWI) downgraded to Hold from Buy at Deutsche Bank with analyst Ross Seymore saying he has no incremental knowledge to support or refute market speculation regarding a potential design win in the upcoming Apple (AAPL) iPhone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
RAJA
07/24/17
NO CHANGE
RAJA
Market Perform
Hibbett warning has negative read-through for Under Armour, says Raymond James
Raymond James analyst Dan Wewer noted that Hibbett Sports' (HIBB) same-store sales warning follows Finish Line's (FINL) Q1 release on June 23 that May sales suffered from weak consumer traffic and difficult product launch comparisons. The read through is negative for Hibbett's vendors, including Under Armour (UAA), said Wewer, who added that it also appears negative for Dick's Sporting Goods (DKS), though he is not sure if Hibbett's sales trends were company specific or reflective of the industry.
UA Under Armour
$18.11

0.75 (4.32%)

XRX Xerox
$30.67

0.24 (0.79%)

07/24/17
07/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Huntsman (HUN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Michael Sison saying he believes HuntsmanClariant will generate "attractive earnings growth" through the end of the decade. He also sees the IPO of Venator (VNTR) as a potential catalyst. 2. Caterpillar (CAT) upgraded to Outperform from Market Perform at BMO Capital with analyst Joel Tiss saying he expects the company to provide five year Earnings Per Share guidance at its September investor event "that could approach" his $16 outlook. 3. Michaels (MIK) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers saying the risk/reward at current share levels is attractive. 4. Xerox (XRX) upgraded to Equal Weight from Underweight at Barclays with analyst Mark Moskowitz saying better market conditions and cost take-outs could help the company improve revenue and margins. 5. Leggett & Platt (LEG) upgraded to Long-Term Buy from Neutral at Hilliard Lyons with analyst Spencer Joyce saying the upgrade is not a call on Q2 results, but does expect positive commentary toward second half 2017 and believes valuation provides a compelling long-term entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
LOOP
07/24/17
INITIATION
Target $36
LOOP
Buy
Xerox initiated with a Buy at Loop Capital
Loop Capital analyst Ananda Baruah initiated Xerox with a Buy and a $36 price target saying the more focused company following the split from its services business will create greater benefits for a company that has a solid history of strong cash flow and believes normalized earnings may reach $4 in 2019.
07/24/17
LEHM
07/24/17
UPGRADE
Target $33
LEHM
Equal Weight
Xerox upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Mark Moskowitz upgraded Xerox to Equal Weight and raised his price target for the shares to $33 from $27. Better market conditions and cost take-outs could help the company improve revenue and margins, Moskowitz tells investors in a research note. The analyst expect the stock's valuation to rerate higher as consensus estimates move up.
01/26/17
SBSH
01/26/17
INITIATION
Target $17
SBSH
Buy
Conduent initiated with a Buy at Citi
Citi analyst Jim Suva started Conduent (CDNT) with a Buy rating and $17 price target. The analyst expects the Xerox (XRX) spinoff to unlock value through cost reductions and an improved focus. He also raised his price target for Xerox shares to $9 from $7.90 and keeps a Buy rating on the name.
LL Lumber Liquidators
$24.71

-0.87 (-3.40%)

07/24/17
WEDB
07/24/17
NO CHANGE
WEDB
Lumber Liquidators Q2 results likely to beat expectations, says Wedbush
Wedbush analyst Seth Basham expects Lumber Liquidators' Q2 results to beat expectations. The analyst says that his checks indicate that the company's traffic has reached a positive turning point, while its ticket totals "remain solid" and its "cost controls should buoy SG&A leverage." He notes that Census data indicates that floor covering retail sales rose sharply last quarter. The analyst keeps a $27 price target and an Outperform rating on the stock.
05/19/17
05/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs analyst Brett Feldman added T-Mobile (TMUS) to the firm's Conviction Buy List and increased its price target to $81 from $74 based on potential capital returns and upside to subscriber growth forecasts. 2. Jefferies analyst John DiFucci upgraded Palo Alto Networks (PANW) to Buy and raised his price target for the shares to $150 from $130. Palo's recent operational weakness has more to do with a major product cycle than sales execution or increased competition, DiFucci tells investors. 3. Oppenheimer analyst Brian Nagel upgraded Lumber Liquidators (LL) to Outperform saying a "potentially prolonged recovery" is starting to take shape under new management. 4. Raymond James analyst Adam Tindle upgraded SYNNEX (SNX) two notches to Strong Buy from Market Perform and established a $122 price target on shares saying key metrics are "poised to inflect." 5. RBC Capital upgraded Autodesk (ADSK) to Outperform from Sector Perform. Analyst Matthew Hedberg says he has increased confidence in the transition of the company's business model after it reported stronger than expected Q1 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/19/17
OPCO
05/19/17
UPGRADE
Target $34
OPCO
Outperform
Lumber Liquidators upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Brian Nagel upgraded Lumber Liquidators to Outperform saying a "potentially prolonged recovery" is starting to take shape under new management. Successful, small-cap turnaround plays have tended to make for some of the best retail stocks, Nagel tells investors in a research note. He has a $34 price target for the shares.
05/10/17
05/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Yelp (YELP) upgraded to Buy from Neutral at Goldman Sachs and to Market Perform from Underperform at Wells Fargo. 2. Coach (COH) upgraded to Buy from Neutral at Goldman Sachs with analyst Lindsay Drucker Mann saying after its acquisition of Kate Spade (KATE), Coach will be a "relative winner in handbags." 3. Lumber Liquidators (LL) upgraded to Outperform from Neutral at Wedbush with analyst Seth Basham saying that the company has stabilized and is poised to return to growth. 4. Occidental Petroleum (OXY) upgraded to Neutral from Underweight at JPMorgan with analyst Phil Gresh citing valuation with the shares. 5. Depomed (DEPO) upgraded to Neutral from Underweight at Piper Jaffray with analyst David Amsellem saying the multiple is now more appropriate following the post-earnings selloff. The analyst lowered his price target for the shares to $10 from $11. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

INFY

Infosys

$14.79

-1.14 (-7.16%)

04:04
08/21/17
08/21
04:04
08/21/17
04:04
Downgrade
Infosys rating change  »

Infosys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 06

    Sep

CPN

Calpine

$14.92

1.42 (10.52%)

04:02
08/21/17
08/21
04:02
08/21/17
04:02
Downgrade
Calpine rating change  »

Calpine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$105.92

7.6 (7.73%)

04:02
08/21/17
08/21
04:02
08/21/17
04:02
Upgrade
Estee Lauder rating change  »

Estee Lauder upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$17.94

-0.24 (-1.32%)

04:01
08/21/17
08/21
04:01
08/21/17
04:01
Upgrade
Physicians Realty Trust rating change  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBMD

Howard Bancorp

$18.05

0.65 (3.74%)

03:58
08/21/17
08/21
03:58
08/21/17
03:58
Upgrade
Howard Bancorp rating change  »

Howard Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SNA

Snap-On

$147.96

-0.86 (-0.58%)

03:56
08/21/17
08/21
03:56
08/21/17
03:56
Downgrade
Snap-On rating change  »

Snap-On downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

E

Eni SpA

03:55
08/21/17
08/21
03:55
08/21/17
03:55
Downgrade
Eni SpA rating change  »

Eni SpA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STO

Statoil

$18.41

0.31 (1.71%)

03:55
08/21/17
08/21
03:55
08/21/17
03:55
Downgrade
Statoil rating change  »

Statoil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REPYY

Repsol

03:55
08/21/17
08/21
03:55
08/21/17
03:55
Downgrade
Repsol rating change  »

Repsol downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$50.49

0.61 (1.22%)

03:55
08/21/17
08/21
03:55
08/21/17
03:55
Downgrade
Total rating change  »

Total downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$16.63

0.23 (1.40%)

03:55
08/21/17
08/21
03:55
08/21/17
03:55
Downgrade
Canadian Solar rating change  »

Canadian Solar downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

03:43
08/21/17
08/21
03:43
08/21/17
03:43
Upgrade
Advance Auto Parts rating change  »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOME

At Home Group

$22.53

-0.22 (-0.97%)

03:40
08/21/17
08/21
03:40
08/21/17
03:40
Initiation
At Home Group initiated  »

At Home Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWW

Grainger

$161.39

-3.21 (-1.95%)

03:40
08/21/17
08/21
03:40
08/21/17
03:40
Initiation
Grainger initiated  »

Grainger reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Jan

NKE

Nike

$54.95

-2.51 (-4.37%)

03:40
08/21/17
08/21
03:40
08/21/17
03:40
Downgrade
Nike rating change  »

Nike downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

03:40
08/21/17
08/21
03:40
08/21/17
03:40
General news
FX Action: USD-CAD has settled near 1.2600 »

FX Action: USD-CAD has…

03:05
08/21/17
08/21
03:05
08/21/17
03:05
General news
FX Update: The dollar majors traded without drama »

FX Update: The dollar…

WUBA

58.com

$53.26

-0.23 (-0.43%)

20:25
08/20/17
08/20
20:25
08/20/17
20:25
Earnings
Notable company reporting before Monday's open »

The notable company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

WUBA

58.com

$53.26

-0.23 (-0.43%)

20:16
08/20/17
08/20
20:16
08/20/17
20:16
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q3 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

WUBA

58.com

$53.26

-0.23 (-0.43%)

20:11
08/20/17
08/20
20:11
08/20/17
20:11
Earnings
58.com reports Q2 EPS 55c, consensus 20c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

, LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

20:02
08/20/17
08/20
20:02
08/20/17
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

LGF.A

Lionsgate

$28.41

0.37 (1.32%)

BGS

B&G Foods

$31.40

-0.3 (-0.95%)

MDLZ

Mondelez

$42.94

-0.47 (-1.08%)

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

  • 06

    Sep

  • 11

    Sep

  • 14

    Sep

  • 18

    Sep

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 27

    Sep

  • 29

    Sep

  • 02

    Nov

  • 25

    Jan

SRE

Sempra Energy

$116.55

0.76 (0.66%)

, BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

18:47
08/20/17
08/20
18:47
08/20/17
18:47
Periodicals
Sempra Energy near deal to acquire Oncor Electric, Bloomberg reports »

Sempra Energy (SRE) is…

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

TWX

Time Warner

$101.19

-0.42 (-0.41%)

, CMCSA

Comcast

$40.52

0.25 (0.62%)

18:34
08/20/17
08/20
18:34
08/20/17
18:34
Hot Stocks
Box Office Battle: 'Hitman's Bodyguard' wins weekend with $21.6M »

Lionsgate' (LGF.A)…

TWX

Time Warner

$101.19

-0.42 (-0.41%)

CMCSA

Comcast

$40.52

0.25 (0.62%)

CMCSK

Comcast

SNE

Sony

$38.77

-0.23 (-0.59%)

FOX

21st Century Fox

$26.79

-0.1 (-0.37%)

FOXA

21st Century Fox

$27.26

-0.09 (-0.33%)

LGF.A

Lionsgate

$28.41

0.37 (1.32%)

DIS

Disney

$100.70

-0.68 (-0.67%)

VIAB

Viacom

$28.59

-0.62 (-2.12%)

VIA

Viacom

$38.80

-3.6 (-8.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 27

    Sep

  • 29

    Sep

GME

GameStop

$21.22

0.12 (0.57%)

, MSFT

Microsoft

$72.49

0.09 (0.12%)

17:08
08/20/17
08/20
17:08
08/20/17
17:08
Hot Stocks
GameStop kicks off nationwide pre-orders for Microsoft Xbox One X »

GameStop (GME) is…

GME

GameStop

$21.22

0.12 (0.57%)

MSFT

Microsoft

$72.49

0.09 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 05

    Sep

GS

Goldman Sachs

$222.15

0.73 (0.33%)

16:48
08/20/17
08/20
16:48
08/20/17
16:48
Periodicals
Goldman Sachs receives approval to trade equities in Saudi Arabia, Reuters says »

Goldman Sachs has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.